+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 80Years
All Genders
ID07174908

Phase 3 Study Comparing IN10018 Plus D-1553 to Standard Therapy for First-Line Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation

Led by InxMed (Shanghai) Co., Ltd. · Updated on 2026-03-03

400

Participants Needed

11

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of IN10018 and D-1553 compared to the standard anti-PD-1 monoclonal antibody therapy with platinum and pemetrexed for treating adults with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC that has a KRAS G12C mutation. This phase III, randomized, open-label study is based on earlier data showing that IN10018 combined with D-1553 may enhance antitumor activity and delay resistance through multiple biological mechanisms. Participants are randomly assigned to one of two treatment groups. One group receives IN10018 100 mg orally once daily and D-1553 600 mg orally twice daily in 21-day cycles until disease progression or unacceptable side effects. The other group receives Tislelizumab 200 mg intravenously every 3 weeks combined with either Carboplatin or Cisplatin intravenously every 3 weeks for up to 4 cycles plus Pemetrexed intravenously every 3 weeks until disease progression. During the study, participants will have regular assessments to monitor tumor response, side effects, and survival. Key outcome measures include progression-free survival over 36 months, response rates, overall survival up to 60 months, and safety evaluations. The study aims to track disease control and duration of response while monitoring adverse events throughout the treatment period.

CONDITIONS

Brief Title

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Research Team

S

Shu Fang Project Manager, bachelor

J

Jack Zhang Clinical Trial Manager, bachelor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here